Skip to main content
SpringerLink
Log in

Immune Tolerance in an Inhibitor Patient with Severe Hemophilia A — Comparison of two Different Treatment Schedules Including Rituximab

  • Conference paper
34th Hemophilia Symposium

  • 573 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kreuz W, Escuriola Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, Heller C, Klarmann D, Klingebiel T; GTH PUP Study Group. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003 Jun;88(6): EREP04

    Google Scholar 

  2. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors — twenty years of the “Bonn protocol”. Vox sang 1996; 70,Suppl 1:30–5

    PubMed  Google Scholar 

  3. Nilsson IM, Hedner U. Immunosuppressive treatment in haemophiliacs with inhibitors for F VIII and factor IX. Scand J Haematol 1976; 16(5):369–82

    PubMed  CAS  Google Scholar 

  4. Kreuz W, Linde R, Escuriola Ettingshausen C, Dunsch D, Köhl U, Figura S, Klingebiel T. A new protocol for inhibitor elimination in high responding hemophilia A patients. Journal of thrombosis and haemostasis 2003, 1suppl 1, july: P1610

    Google Scholar 

  5. Wermes C, von Depka M, Welte K, Sykora KW. Long-term remission after the treatment of factor IX inhibitors in severe haemophilia B. Journal of thrombosis and haemostasis 2001 Suppl.1, P1826

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abt. Hämophilie/Medizinische Poliklinik, Medizinische Hochschhule Hannover, D-Hannover, Germany

    Frau Dr. C. Wermes & Dr. M. von Depka Prondzinski

  2. Pädiatrishche Hämatologie und Onkologie, Medizinische Hochschule Hannover, D-Hannover, Germany

    Frau Dr. I. Wieland

Authors
  1. Frau Dr. C. Wermes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frau Dr. I. Wieland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. M. von Depka Prondzinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. W. Sykora
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hemophilia Center, Dept. of Internal Medicine, University Hospital, Theodor-Stern-Kai 7, D-60590, Frankfurt am Main, Germany

    I. Scharrer

  2. Dept. of Hemostaseology, University Hospital, Ziemssenstr. 1a, D-80336, München, Germany

    W. Schramm

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Medizin Verlag Heidelberg

About this paper

Cite this paper

Wermes, C., Wieland, I., von Depka Prondzinski, M., Sykora, K.W. (2005). Immune Tolerance in an Inhibitor Patient with Severe Hemophilia A — Comparison of two Different Treatment Schedules Including Rituximab. In: Scharrer, I., Schramm, W. (eds) 34th Hemophilia Symposium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27022-1_41

Download citation

  • DOI: https://doi.org/10.1007/3-540-27022-1_41

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-22886-8

  • Online ISBN: 978-3-540-27022-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation